| Date Filed | Type | Description |
| 06/05/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 05/26/2023 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
| 05/26/2023 |
SC 13D/A
| TAKEDA PHARMACEUTICAL CO LTD reports a 0% stake in Calithera Biosciences, Inc. |
| 03/20/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/14/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/14/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/03/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Calithera Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| PRIMECAP MANAGEMENT CO reports a 8.2% stake in Calithera Biosciences, Inc. |
| 02/09/2023 |
SC 13G/A
| PRIMECAP MANAGEMENT CO reports a 4.1% stake in Calithera Biosciences, Inc. |
| 02/08/2023 |
SC 13G/A
| INCYTE CORP reports a 0% stake in Calithera Biosciences, Inc. |
| 01/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 01/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/09/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 12/08/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 09/29/2022 |
8-K
| Quarterly results |
| 08/16/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/16/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/23/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
SC 13D
| TAKEDA PHARMACEUTICAL CO LTD reports a 13.2% stake in Calithera Biosciences, Inc. |
| 04/20/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/20/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/12/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
|